Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Tizanidine Chronic Pain Syndrome	Stanford University	P4	BB (68)
Tucidinostat Peripheral T-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P4	BB (68)
Umbellatine Abdominal Obesity-Metabolic Syndrome	Nanjing First Hospital, Nanjing Medical University	P4	BB (68)
Valproic Acid Traumatic Brain Injury	Northwestern University	P4	BB (68)
Vandazole Colorectal Neoplasm	Helsinki University Central Hospital	P4	BB (68)
(+)-Vincristine B-Cell Non-Hodgkin Lymphoma	Mwanasha Merrill, MD	P4	BB (68)
(+)-Vincristine Metastatic Neoplasm	Eli Lilly and Company	P4	BB (68)
(+)-Vincristine Primary Mediastinal Large B-Cell Lymphoma	Sun Yat-sen University	P4	BB (68)
Vitamin D Epilepsy	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	P4	BB (68)
Warfarin Portal Vein Thrombosis	Kafrelsheikh University	P4	BB (68)
Warfarin Transient Ischemic Attack	Seoul National University Hospital	P4	BB (68)
Zonisamide Epilepsy	Azurity Pharmaceuticals	P4	BB (68)
Adriamycin Ovarian Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	BB (68)
Adriamycin Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin High Grade B-Cell Lymphoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin Ovarian Cancer	Genmab	P3	BB (68)
Adriamycin Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin Ovarian Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin Undifferentiated Ovarian Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin Childhood Acute Lymphoblastic Leukemia	Tanja Andrea Gruber	P3	BB (68)
Atezolizumab Triple-Negative Breast Carcinoma	European Institute of Oncology	P3	BB (68)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription Hematologic Disorder	Vertex Pharmaceuticals Incorporated	P3	BB (68)
Azacitidine Myelodysplastic Syndrome	The First Affiliated Hospital of Soochow University	P3	BB (68)
Bicalutamide Prostate Adenocarcinoma	OHSU Knight Cancer Institute	P3	BB (68)

Showing 1426 to 1450 of 42,301 assets

PreviousPage 58 of 1693Next